Answers are grounded in this paper and cite their sources.
The personalized cancer vaccine EVX-01 (Evaxion) combined with the PD-1 immune checkpoint inhibitor (ICI) pembrolizumab induced an overall response rate (ORR) of 69% after two years, with tumor red...
No takes yet. Share an insight, caveat, or question.
Ellis et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: